Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breathe easier: mindfulness meets pulmonary rehab in new COPD trial

NCT ID NCT07195838

Symptom relief Sponsor: The University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new program called Mindful-Breath for people with chronic obstructive pulmonary disease (COPD). The program combines mindfulness, breathing exercises, and lifestyle coaching through group sessions and chat support. Researchers want to see if it is feasible and acceptable, and whether it helps reduce stress and increase physical activity. Sixty participants will be randomly assigned to either the Mindful-Breath program or a standard education session.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hybrid mindfulness-based pulmonary rehabilitation program
What this could lead to
If successful, this could offer a new, accessible way to help COPD patients manage stress, increase physical activity, and improve well-being.
What could go wrong
This is a small pilot study with only 60 participants, so results may not apply to everyone. It focuses on feasibility, not yet on proving effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: 50-80 years * Sex: Male or female * Education level: Primary or above * Diagnosis: COPD (Baseline FEV1 \<80% and FEV1/FVC \<70% of predicted normal values) * Severity of COPD: Stage I to IV * Group of COPD: Group B, or E, based on 2024 GOLD guideline (36) * Clinical stability: No acute exacerbation in the past 4 weeks. Patients with recent acute exacerbation in the past 4 weeks will be screened again in subsequent follow-up. * Moderate stress: PSS score ≥14 (28) * Access to a mobile device (e.g., a smartphone, tablet, or laptop) with internet connectivity * Ability to read, communicate, and provide written consent in Chinese. Exclusion Criteria: * Engaging in \>60 minutes/week of moderate PA based on American Lung Association guidelines * Recent or ongoing receipt of other pharmacological/behavioral trials within the past 3 months * Contraindications or severe comorbidities that may limit full participation (mental diseases, deafness, limb activity disorder, coronary heart disease, arterial aneurysm, uncontrolled hypertension, pregnancy, etc) * Co-existing respiratory diseases (Asthma/interstitial lung disease/bronchiectasis) or active malignancies * Very severe COPD requiring long-term oxygen therapy or home non-invasive ventilation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease (COPD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease Sedentary Behavior

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease (COPD) Mindfulness Pulmonary rehabilitation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • School of Nursing, The University of Hong Kong, Hong Kong

    RECRUITING

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.